not tagged
beigene
['cll', 'beigene']
in case you missed it, at #eha2023 we presented new follow-up results from our pivotal phase 3 and phase 2 studies in cll and some other b-cell malignancies and post hoc safety analyses reinforcing beigene s btk inhibitor's potential across various b-cell malignancies. 
We’re a global biotech developing innovative oncology medicines & making them more accessible to cancer patients worldwide. Community guidelines: https://t.co/bZCHuaXRQ0